Moderna has announced an agreement in principle with the UK government to build an mRNA Innovation and Technology Center in the country.

The mRNA vaccine-producing facility is anticipated to offer access to quick pandemic response capabilities and the company’s respiratory virus vaccine candidates.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Moderna plans to expand in the UK via investments in research and development (R&D) activities.

Moderna CEO Stéphane Bancel said: “We are excited to be able to continue our collaboration with the UK government and Vaccine Taskforce with this new mRNA Innovation and Technology Center in the UK. The UK has established a world-class life sciences and research community.
“We are committed to global public health, and as we continue to expand internationally, we are pleased to bring local mRNA manufacturing to the UK. We look forward to establishing our R&D activities and capabilities in the country.”

Moderna anticipates its facility to manufacture mRNA vaccines, including vaccines against Covid-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines

The facility is expected to be activated urgently to support the country’s quick pandemic response capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moderna is collaborating with the National Institute for Health Research (NIHR) on a Phase 3 study to examine the company’s bivalent Omicron-containing booster candidate (mRNA-1273.214) .

Separately, the UK government bought 60 million doses of Moderna’s Covid-19 vaccine, which may include authorised booster vaccine candidates for delivery this year and next year.
——————————————————————————————————————
Image: Moderna anticipates its facility to manufacture mRNA vaccines. Credit: Arek Socha from Pixabay.